Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egyptian International Pharmaceutical Investments (CAI:PHAR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Egyptian International Pharmaceutical Investments PS Ratio Related Terms
Egyptian International Pharmaceutical Investments PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments PS Ratio Chart
Egyptian International Pharmaceutical Investments Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments PS Ratio vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Egyptian International Pharmaceutical Investments's Share Price of today is E£90.70. Egyptian International Pharmaceutical Investments's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£43.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a PS Ratio of 2.07 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 42% above median its historical median of 1.46. Over the past decade, Egyptian International Pharmaceutical Investments' PS Ratio has ranged from 0.74 to 4.92. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #440 out of 952 companies in the Drug Manufacturers industry, placing it in the top 46.2%.
Is Egyptian International Pharmaceutical Investments' PS Ratio too high?
Egyptian International Pharmaceutical Investments' current PS Ratio of 2.07 is 42% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 4.92. The Drug Manufacturers industry median PS Ratio is 2.29. Egyptian International Pharmaceutical Investments' value of 2.07 is 9.6% below this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #440 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #440 out of 952 companies for PS Ratio. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median PS Ratio is 2.29. Egyptian International Pharmaceutical Investments' value of 2.07 is 9.6% below this benchmark. Historically, Egyptian International Pharmaceutical Investments' own PS Ratio has ranged from 0.74 to 4.92 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 2.29, Egyptian International Pharmaceutical Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current PS Ratio of 2.07 is 9.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current PS Ratio is 2.07, which is 42% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.88, compared to a current price of E£90.70 — trading 51.5% above its estimated fair value. The current PS Ratio is 2.07, which is 42% above median its 10-year median of 1.46 and 9.6% below the Drug Manufacturers industry median of 2.29. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current PS Ratio is 2.07 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£90.70 is trading 51.5% above its estimated GF Value™ of E£59.88.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
PS Ratio: 2.07 (42% above median its 10-year median of 1.46)
GF Value™: E£59.88 vs. price of E£90.70 (51.5% above fair value)
Industry Position: 9.6% below the Drug Manufacturers median (#440 of 952)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
